Published: June 5, 2025
The strategic partnership between OURA and Dexcom will bridge two market segments, blurring the bounds between medtech and consumer health.
Medtech company Dexcom announced it has partnered with ŌURA, makers of the Oura Ring. Under the terms of the partnership, Dexcom’s glucose sensors will be integrated with the Oura Ring, which is a market-leading smart ring that tracks metrics such as activity and sleep.
Dexcom also invested US$75mn in ŌURA in a series D funding round, bringing the latter company’s valuation to more than US$5bn after the US$200mn fund raising. The two companies will co-market and cross-sell each other’s products, with the first app integration due to launch within the next few months. Neither company has supplied more details on what we can expect from the collaboration.
Matt Dolan, executive vice president of strategy and corporate development at Dexcom, said of the partnership: “This powerful combination will attract new shared customers who want to better understand the link between activity, sleep, nutrition and their glucose.”
A new direction
Headquartered in San Diego, Dexcom is a market leader in diabetes technology. The company was founded in 1999 and launched its first biosensor five years later. Its SEVEN system, which achieved FDA approval in 2007, was among the first continuous glucose monitors (CGMs) to hit the market.
Since then, the company says it has changed the landscape of diabetes monitoring, having eliminated more than 11bn fingerprick tests. According to GlobalData, the company occupies almost three-quarters of the CGM market in the US.
ŌURA, meanwhile, is a Finnish health technology startup, founded in 2013. Its Oura Ring collects health data from the wearer’s finger, in much the same way as a regular activity bracelet.